tbuckley/cabot-search huggingface dataset:
Abstract 1223: Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein.
Authors: Maria Carmen Ochoa, Pedro Berraondo, Ignacio Melero
Journal: Cancer Research (2013)

Abstract Interleukin 15 (IL-15) effects on CD8 T and NK lymphocytes hold promise to treat cancer. Fusion proteins have been engineered to provide IL-15 receptor alpha (IL-15Rα) mediated trans-presentation to lymphocytes and extend the plasma half-life of the cytokine. In this study, we report on a triple fusion protein combining apolipoprotein A-I, IL-15 and IL-15Rα’s sushi domain. Apolipoprotein A-I conveys IL-15 to high-density lipoproteins (HDL), from which the cytokine is trans-presented by the IL-15Rα's sushi domain. Such a construction was tested by hydrodynamic gene transfer to the liver of mice. Lethal toxicity was observed upon injection of 10μg of the expression plasmid. Mice died from an acute lymphocytic pneumonitis in which T and NK cells dominate a severe inflammatory infiltrate. Importantly, mice devoid of NK cells were not susceptible to such toxicity and mice lacking granzymes A and B also survived the otherwise lethal gene transfer. Lower plasmid doses (&amp;lt;2.5μg) were tolerated and dramatically increased the numbers of NK and memory CD8 T lymphocytes in the liver, spleen and lungs, to the point of rescuing the deficiency of such lymphocyte subsets in IL-15Rα-/- mice. Doses of plasmid within the therapeutic window successfully treated metastatic tumor models, including B16OVA lung metastasis of melanoma and MC38 colon cancer liver metastasis. Sushi-IL15-Apo as a recombinant protein was also bioactive in vivo, became conjugated to HDL and displayed immuno-therapeutic effects against metastatic disease. Citation Format: Maria Carmen Ochoa, Pedro Berraondo, Ignacio Melero. Antitumor immunotherapeutic and toxic properties of an HDL-conjugated chimeric IL-15 fusion protein. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 1223. doi:10.1158/1538-7445.AM2013-1223
Automated Identification of Infarcted Myocardium Tissue Characterization Using Ultrasound Images: A Review
Authors: Vidya Sudarshan, U. Rajendra Acharya, Eddie Yin-Kwee Ng, Chou Siaw Meng, Ru San Tan, Dhanjoo N. Ghista
Journal: IEEE Reviews in Biomedical Engineering (2014)

Myocardial infarction (MI) or acute myocardial infarction commonly known as heart attack is one of the major causes of cardiac death worldwide. It occurs when the blood supply to the portion of the heart muscle is blocked or stopped causing death of heart muscle cells. Early detection of MI will help to prevent the infarct expansion leading to left ventricle (LV) remodeling and further damage to the cardiac muscles. Timely identification of MI and the extent of LV remodeling are crucial to reduce the time taken for further tests, and save the cost due to early treatment. Echocardiography images are widely used to assess the differential diagnosis of normal and infarcted myocardium. The reading of ultrasound images is subjective due to interobserver variability and may lead to inconclusive findings which may increase the anxiety for patients. Hence, a computer-aided diagnostic (CAD) technique which uses echocardiography images of the heart coupled with pattern recognition algorithms can accurately classify normal and infarcted myocardium images. In this review paper, we have discussed the various components that are used to develop a reliable CAD system.
Nonproducer malignant tumor cells with rescuable sarcoma virus genome isolated from a recurrent Moloney sarcoma.
Authors: E Weiland, M Mussgay, F Weiland
Journal: The Journal of Experimental Medicine (1978)

Cells from a secondary tumor developing at the site of a regressed Moloney sarcoma virus-induced tumor could be passaged in adult STU mice by intramuscular and intraperitoneal inoculation. The tumors induced by these cells, as well as by a cell line derived from it, grew progressively and led to death of the animals between 3 and 7 wk after tumor transplantation. No evidence for production of virus from these cells was obtained or for the presence of viral antigens (p30, gp69/71). From both cell variants, sarcoma virus genome could be rescued by infection with helper virus, resulting in the establishment of a cell line producing focus- and XC plaque-forming virus. The rescued producer cells very frequently also produced tumors which finally grew progressively. The nonproducer cells were not immunogenic, as was demonstrated in cross transplantation tests and in studies for cell-mediated cytotoxicity (CMC) and complement-dependent antibody-mediated cytotoxicity (AMC). The producer cells, however, were demonstrated to possess a strong immunogenicity. The nonproducer cells, though nonimmunogenic, revealed a weak immunosensitivity when used for challenge in the transplantation protection assay or as target cell for the demonstration of AMC and CMC, if the immune response was induced by cells producing the sarcoma-helper virus complex, but not by cells producing only helper virus. The nonproducer cells, as well as their rescued producer derivative, showed a stronger reactivity with cytotoxic antibodies than with cytotoxic cells, whereas the helper virus-producing cell line was comparably suitable as target cell for AMC and CMC. The recurrence of a regressed Moloney sarcoma is assumed to be the result of the occurrence of transformed nonproducer cells escaping immune destruction, and not as a consequence of a depleted immune resistance in the host.
Elongated Styloid Process as a Cause of Transient Ischemic Attacks
Authors: Joon Ho Song, Sung Ki Ahn, Chul Bum Cho
Journal: JAMA Neurology (2013)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Neurology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Neurology journal
Differential proteome analysis of TRAP-activated platelets: involvement of DOK-2 and phosphorylation of RGS proteins
Authors: Angel García, Sripadi Prabhakar, Sascha Hughan, Tom W. Anderson, Chris J. Brock, Andrew C. Pearce, Raymond A. Dwek, Steve P. Watson, Holger F. Hebestreit, Nicole Zitzmann
Journal: Blood (2003)
Post-ischemic PKC inhibition impairs myocardial calcium handling and increases contractile protein calcium sensitivity
Authors: Christof Stamm, Ingeborg Friehs, Douglas B. Cowan, Hung Cao-Danh, Sabrena Noria, Mamoru Munakata, Francis X. McGowan, Pedro J. del Nido
Journal: Cardiovascular Research (2001)

Protein kinase C (PKC) activation impairs contractility in the normal heart but is protective during myocardial ischemia. We hypothesized that PKC remains activated post-ischemia and modulates myocardial excitation-contraction coupling during early reperfusion.Langendorff-perfused rabbit hearts where subjected to 25 min unmodified ischemia and 30 min reperfusion. Total PKC activity was measured, and the intracellular translocation pattern of PKC-alpha, -delta, -epsilon, and -eta assessed by immunohistochemistry and fractionated Western immunoblotting. The PKC-inhibitors chelerythrine and GF109203X were added during reperfusion and also given to non-ischemic hearts. Measurements included left ventricular function, intracellular calcium handling measured by Rhod-2 spectrofluorometry, myofibrillar calcium responsiveness in beating and tetanized hearts, and metabolic parameters.Total PKC activity was increased at end-ischemia and remained elevated after 30 min of reperfusion. The translocation pattern indicated PKC-epsilon as the main active isoform during reperfusion. Post-ischemic PKC inhibition affected mainly diastolic relaxation, with lesser effect on contractility. Both PKC inhibitors increased the Ca(2+) responsiveness of the myofilaments as indicated by a leftward shift of the calcium-to-force relationship and increased maximum calcium activated tetanic pressure. Diastolic Ca(2+) removal was delayed and the post-ischemic [Ca(2+)](i) overload further exacerbated. Depressed systolic function was associated with a lower amplitude of [Ca(2+)](i) transients.PKC is activated during ischemia and remains activated during early reperfusion. Inhibition of PKC activity post-ischemia impairs functional recovery, delays diastolic [Ca(2+)](i) removal, and increases Ca(2+) sensitivity of the contractile apparatus, resulting in impaired diastolic relaxation. Thus, post-ischemic PKC activity may serve to restore post-ischemic Ca(2+) homeostasis and attenuate contractile protein calcium sensitivity during the period of post-ischemic [Ca(2+)](i) overload.
Primary preventive and secondary interventionary effects of acetyl-L-carnitine on diabetic neuropathy in the bio-breeding Worcester rat.
Authors: A A Sima, H Ristic, A Merry, M Kamijo, S A Lattimer, M J Stevens, D A Greene
Journal: Journal of Clinical Investigation (1996)

The abnormalities underlying diabetic neuropathy appear to be multiple and involve metabolic neuronal and vasomediated defects. The accumulation of long-chain fatty acids and impaired beta-oxidation due to deficiencies in carnitine and/or its esterified derivatives, such as acetyl-L-carnitine, may have deleterious effects. In the present study, we examined, in the diabetic bio-breeding Worcester rat, the short- and long-term effects of acetyl-L-carnitine administration on peripheral nerve polyols, myoinositol, Na+/K+ -ATPase, vasoactive prostaglandins, nerve conduction velocity, and pathologic changes. Short-term prevention (4 mo) with acetyl-L-carnitine had no effects on nerve polyols, but corrected the Na+/K+ -ATPase defect and was associated with 63% prevention of the nerve conduction defect and complete prevention of structural changes. Long-term prevention (8 mo) and intervention (from 4 to 8 mo) with acetyl-L-carnitine treatment normalized nerve PGE(1) whereas 6-keto PGF(1-alpha) and PGE(2) were unaffected. In the prevention study, the conduction defect was 73% prevented and structural abnormalities attenuated. Intervention with acetyl-L-carnitine resulted in 76% recovery of the conduction defect and corrected neuropathologic changes characteristic of 4-mo diabetic rats. Acetyl-L-carnitine treatment promoted nerve fiber regeneration, which was increased two-fold compared to nontreated diabetic rats. These results demonstrate that acetyl-L-carnitine has a preventive effect on the acute Na+/- K+_ATPase defect and a preventive and corrective effect on PGE1 in chronically diabetic nerve associated with improvements of nerve conduction velocity and pathologic changes.
Quality improvement analysis of <i>HER2</i> FISH testing in breast cancer in response to the new ASCO/CAP guidelines.
Authors: M Fang, V Thalody, S Tannenbaum
Journal: Cancer Research (2009)

Abstract Abstract #3013 Background: The new ASCO/CAP guidelines for HER2 testing in breast cancer redefined the interpretation of HER2 FISH testing result. A new category of equivocal result is defined as FISH ratio of 1.8-2.2. Patients with equivocal results constitute a poorly studied subgroup with uncertain association of test scores to benefit from HER2-directed therapy. Additional quality control and quality assurance recommendations were also detailed in the guideline. As part of our institutional effort for quality improvement of HER2 testing, we reviewed the FISH HER2 testing performed in our institution for the past four years.&amp;#x2028; Methods: The FDA-approved PathVision HER2 FISH kit (Abbott Molecular, CA) was used for all FISH testing. The Herceptest ParmDx antibody (Dako Cytomation) and the Neu-Her2/Cerb-2 antibody (Vision Biosystems) were used for all IHC testing. The new ASCO/CAP interpretation criteria were applied to the FISH enumeration results and compared with the IHC results and interpretation. Correlation with clinical decision of trastuzumab therapy and clinical outcome was reviewed.&amp;#x2028; Results: A total of 554 samples between 2004 and 2008 were tested for HER2 FISH. According to the new interpretation criteria, 12.8% of the samples had amplified values and 3.8% of the samples had equivocal values. IHC was negative for Her2 for all the samples with equivocal FISH results. Only one patient was treated with trastuzumab. In addition to this equivocal category, some samples showed genetic heterogeneity with some of the tumor showing cells with HER2 amplification whereas cells at different areas of the same tumor were not amplified. Half of these patients were treated and the remaining 50% were not. The discordant rate between FISH and IHC was 3.6% overall, and aneusomy 17 may explain some of the discordance. Of patients with discordant HER2 results by FISH and IHC, physicians' decision to treat with trastuzumab or not appeared to be based on either FISH or IHC with equal frequencies.&amp;#x2028; Conclusion: Due to small sample size and retrospective nature of this review, outcome data was uninformative in these small cohorts. As suggested by the ASCO/CAP expert panel, pooling data from all adjuvant trastuzumab trails on subjects with equivocal results would be helpful to provide an evidence base for physicians to make treatment decisions. Alternatively, we are beginning to explore molecular expression profiles to see whether some of these equivocal or discordant cases behave more like HER2 positive or negative patients. Citation Information: Cancer Res 2009;69(2 Suppl):Abstract nr 3013.
THE TYPE OF PHAGOCYTIC CELL AND ITS RELATIVE PROPORTIONS IN HUMAN BONE MARROW AND SPLEEN, AS IDENTIFIED BY THE SUPRAVITAL TECHNIQUE, WITH SPECIAL REFERENCE TO PERNICIOUS ANEMIA
Authors: Charles A. Doan
Journal: The Journal of Experimental Medicine (1926)

In general, there is a reversal of the normal in the ratio of clasmatocytes in the spleen to clasmatocytes in the bone marrow in pernicious anemia, with a marked tendency toward the phagocytosis of young, immature, nucleated red blood cells in the bone marrow. The peripheral blood picture suggests that these cells had never been in circulation. The observations made do not indicate that the spleen takes any directly active part in an increased destruction of blood in pernicious anemia.
Effective Compliance during the First 3 Months of Continuous Positive Airway Pressure
Authors: JEAN LOUIS PÉPIN, JEAN KRIEGER, DANIEL RODENSTEIN, ANDRÉ CORNETTE, EMILIA SFORZA, PIERRE DELGUSTE, CHRYSTÈLE DESCHAUX, VÉRONIQUE GRILLIER, PATRICK LÉVY
Journal: American Journal of Respiratory and Critical Care Medicine (1999)

Effective compliance (time spent at the effective pressure) with nasal CPAP in obstructive sleep apnea has been reported to be poor. The aim of our study was to evaluate effective compliance in a large European multicenter study. One hundred twenty-one consecutive newly treated patients (initial apnea–hypopnea index [AHI] = 62.0 ± 29.5/h, AHI under CPAP = 6.4 ± 8.1/h, CPAP pressure = 8.7 ± 2.6 cm H2O, BMI = 33.1 ± 6.8 kg/m2) were randomly allocated to a group with (MC+) (n = 58) or without (MC−) (n = 63) a control unit measuring effective compliance at 1, 2, and 3 mo, which was compared with the built-in time counter data. MC+ data were 94 ± 10, 98 ± 5, and 96 ± 9% of counter data at 1, 2, and 3 mo, respectively. Using criteria of regular use already reported in the literature (at least 4 h of nCPAP per day of use and nCPAP administered more than 70% of the days) we found 77, 82, and 79% compliant patients at 1, 2, and 3 mo, respectively, 79% of the patients meeting these criteria each month. Although there were no pulmonary functions or polysomnographic differences between the two subgroups, the compliant patients did report a greater improvement in minor symptoms. We found a close correlation between effective use of CPAP and the machine run time. The main result of our study was a higher effective compliance than previously reported, approximately 80% of the patients being regular users versus 46% in a previously published study. This may result from different technical and medical follow-up.
Diagnosis and Treatment of Malignant Carcinoid Syndrome
Authors: Robert J. Levine
Journal: JAMA (1975)

<h3>To the Editor.—</h3> The article, "Diagnosis and Treatment of Malignant Carcinoid Syndrome," by Dr. A. L. Ureles (229:1346, 1974) contains several serious errors. In this letter I shall concentrate on those that have substantial patient-care implications. Documentation of the statements I shall make may be found in a recent textbook chapter<sup>1</sup>that will also provide access to the primary literature from which they are derived. I shall restrain myself from taking issue with the several incorrect statements that are likely to be more of interest to professional pedants than to practicing physicians who wish to understand how to safely and effectively diagnose and treat the carcinoid syndrome. The dose of epinephrine that Dr. Ureles designates for intravenous administration to perform the epinephrine provocative test is 5 mg. He concludes: "Reports of severe vascular collapse and paradoxical hypertension would suggest, however, that<i>pressor amines should be avoided in the evaluation</i>
Influence on clinical practice of routine intra-partum fetal monitoring.
Authors: J Sibanda, R W Beard
Journal: BMJ (1975)

An attempt has been made to monitor by continuous fetal heart rate according all women admitted in labour. Altogether 85% of the 1070 patients delivered at one hospital were monitored in 1973 and 92% in 1974. Perinatal mortality fell significantly from levels in preceding years to 15-8 and 11-7 per 1000 births, respectively, in 1973 and 1974. The fall was primarily due to the elimination of intra-partum stillbirths and a significant reduction in neonatal mortality. The incidence of caesarean sections also fell from 9-7% in 1973 to 5-8% in 1974. All patients should be monitored because it is impossible to predict reliably intra-partum fetal distress from maternal "high-risk" factors present before the onset of labour.
Prevention of Early Sudden Circulatory Collapse After the Norwood Operation
Authors: Nilto C. De Oliveira, David A. Ashburn, Faizah Khalid, Harold M. Burkhart, Ian T. Adatia, Helen M. Holtby, William G. Williams, Glen S. Van Arsdell
Journal: Circulation (2004)

Background— After modifications in our perioperative management protocol, we have observed a decrease in sudden circulatory collapse after the Norwood operation. The current study examines early outcomes after the Norwood operation in our unit in an attempt to identify variables that may have altered the risk of unexpected circulatory collapse. Methods and Results— We studied 105 consecutive neonates who underwent a Norwood operation in our institution. Our treatment protocol has changed in the past 3 years to include the use of alpha-blockade with phenoxybenzamine (POB) for systemic afterload reduction and selective cerebral perfusion. Forty-eight infants had selective cerebral perfusion. Forty-two infants received POB. Sixty patients had hypoplastic left heart syndrome. There was no difference in age, diagnosis, number of neonates with weight &lt;2.5 kg, aortic size diameter &lt;2 mm, highest preoperative lactate level, and shunt size indexed to body weight among patients with or without use of POB. Twenty-five infants had circulatory collapse during the first 72 hours. Twelve of them could be explained by technical issues. Thirteen others who appeared clinically stable had early sudden circulatory collapse without an apparent cause. Sixteen out of 25 neonates died. Of those with technical problems, 8 out of 12 died. Based on the hazard function, 3 incremental risk factors for early circulatory collapse were technical issue at operation ( P &lt;0.001), longer cross-clamp time ( P &lt;0.007), and no use of POB ( P &lt;0.002). For a technically successful operation, freedom from circulatory collapse at 72 hours is 95% with the use of POB versus 69% without ( P &lt;0.002). Diagnosis, aortic size, atrioventricular valve function, birth weight, age at operation, and total circulatory arrest time and were not predictive of early sudden circulatory collapse. Conclusion— Recent changes in our treatment protocol have resulted in a decrease incidence of sudden circulatory collapse after the Norwood operation. Optimal surgical technique is the most important predictor of early survival. The use of aggressive afterload reduction with POB reduced the risk of early sudden arrest.
The effects of coronary angioplasty and reperfusion on distribution of myocardial flow.
Authors: D W Wahr, T A Ports, E H Botvinick, M Dae, N Schechtmann, J Huberty, R S Hattner, J W O'Connell, K Turley
Journal: Circulation (1985)

To assess the effects of angioplasty (PTCA) and intracoronary streptokinase (ICSK) on relative myocardial perfusion, we administered 99mTc-macroaggregated albumin (MAA) to the uninvolved coronary artery before successful PTCA in 33 patients and before successful infusion of ICSK in eight patients and of 111In-MAA into the same vessel after the intervention. In 10 patients who underwent PTCA, MAA was injected into the involved, instrumented coronary artery. Computer-processed images were acquired in registry and compared. Similar scintigraphic studies were performed in six control patients and in 11 in whom planned interventions were not performed or were unsuccessful. Distribution of MAA was also compared with angiographic results and with the distribution of 201Tl on images obtained in patients at rest or on redistribution images obtained before and soon after intervention in 22 patients. In control patients and those studied after aborted or unsuccessful intervention, scintigraphic results showed excellent correlation with the angiographic anatomy and were without serial change. When MAA was injected into the uninvolved vessel, the scintigram revealed evidence of collateral perfusion with retraction of the perfusion zone from that of the involved coronary in 19 of 33 patients undergoing PTCA and in three of eight of those receiving ICSK. When MAA was injected into the involved artery, a relative increase in perfusion was seen in eight of 10 patients after PTCA. Although 30 patients demonstrated scintigraphic evidence of collateral vessels, only 10 patients had angiographic evidence of collateral circulation before intervention. The distribution of 201Tl demonstrated little change in its global pattern and regions previously supplied by collaterals were generally well perfused after intervention. Coronary collateral perfusion may be inapparent angiographically and regress rapidly after angioplasty or reperfusion. Native perfusion is generally and quickly restored after successful PTCA or ICSK infusion, which obviates the need for collaterals. After intervention, the distribution of total perfusion may not change, but its regional source may demonstrate beneficial alterations, shifting from collateral to native circulation.